IMPRIND - Inhibiting Misfolded protein Propagation In Neurodegenerative Diseases – is an international joint consortium of academic groups and pharma industry devoted to investigate how aggregated proteins contribute to the progression of Alzheimer’s and Parkinson’s diseases and facilitate development of new treatments. IMPRIND was launched by The Innovative Medicines Initiative (IMI) on 1 March 2017 and is funded jointly by the Horizon2020 Program of the European Commission, the IMI Initiative, and the Swiss State Secretariat for Education, Research and Innovation (SERI).

Prof. Poul Henning Jensen joins the IMPRIND consortium as a research partner to develop and validate cellular assays to screen for drug candidates that can protect against the toxicity of different alpha-synuclein aggregate strains.

Read more about the IMPRIND project here.